FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:861-869 September 20, 2001 Number 12 Next

	Full Text PDF Editorial by Hostetter, T. H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin–angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available for patients with type 2, the most common form of diabetes. We assessed the role of the angiotensin-II–receptor antagonist losartan in patients with type 2 diabetes and nephropathy.

Methods A total of 1513 patients were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once daily) with placebo, both taken in addition to conventional antihypertensive treatment (calcium-channel antagonists, diuretics, alpha-blockers, beta-blockers, and centrally acting agents), for a mean of 3.4 years. The primary outcome was the composite of a doubling of the base-line serum creatinine concentration, end-stage renal disease, or death. Secondary end points included a composite of morbidity and mortality from cardiovascular causes, proteinuria, and the rate of progression of renal disease.

Results A total of 327 patients in the losartan group reached the primary end point, as compared with 359 in the placebo group (risk reduction, 16 percent; P=0.02). Losartan reduced the incidence of a doubling of the serum creatinine concentration (risk reduction, 25 percent; P=0.006) and end-stage renal disease (risk reduction, 28 percent; P=0.002) but had no effect on the rate of death. The benefit exceeded that attributable to changes in blood pressure. The composite of morbidity and mortality from cardiovascular causes was similar in the two groups, although the rate of first hospitalization for heart failure was significantly lower with losartan (risk reduction, 32 percent; P=0.005). The level of proteinuria declined by 35 percent with losartan (P<0.001 for the comparison with placebo).

Conclusions Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.

Source Information

From the Renal Division, Brigham and Women's Hospital, Boston (B.M.B.); the Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia (M.E.C.); the Department of Clinical Pharmacology, University of Groningen, Groningen, the Netherlands (D.Z.); the Department of Medicine, Hennepin County Medical Center, Minneapolis (W.F.K.); the Renal Division, Emory University, Atlanta (W.E.M.); Steno Diabetes Center, Gentofte, Denmark (H.-H.P.); Laboratori Negri Bergamo, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy (G.R.); and Merck Research Laboratories, Blue Bell, Pa. (S.M.S., Z.Z., S.S.).

Address reprint requests to Dr. Brenner at the Renal Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at bbrenner{at}partners.org.

Full Text of this Article

This article has been cited by other articles:

• HIRSCH, S. (2008). An update on proteinuric chronic kidney disease: The dual-goal approach. Cleveland Clinic Journal of Medicine 75: 705-713 [Abstract] [Full Text]  
• Galle, J., Schwedhelm, E., Pinnetti, S., Boger, R. H., Wanner, C., on behalf of the VIVALDI investigators, (2008). Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 23: 3174-3183 [Abstract] [Full Text]  
• Peti-Peterdi, J., Kang, J. J., Toma, I. (2008). Activation of the renal renin-angiotensin system in diabetes--new concepts. Nephrol Dial Transplant 23: 3047-3049 [Full Text]  
• Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., Kawamori, R. (2008). Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93: 3671-3689 [Abstract] [Full Text]  
• Izuhara, Y., Sada, T., Yanagisawa, H., Koike, H., Ohtomo, S., Dan, T., Ito, S., Nangaku, M., van Ypersele de Strihou, C., Miyata, T. (2008). A Novel Sartan Derivative With Very Low Angiotensin II Type 1 Receptor Affinity Protects the Kidney in Type 2 Diabetic Rats. Arterioscler. Thromb. Vasc. Bio. 28: 1767-1773 [Abstract] [Full Text]  
• Franks, A. M, O'Brien, C. E, Stowe, C. D, Wells, T. G, Gardner, S. F (2008). Candesartan Cilexetil Effectively Reduces Blood Pressure in Hypertensive Children. The Annals of Pharmacotherapy 42: 1388-1395 [Abstract] [Full Text]  
• Pan, Y., Guo, L. L., Jin, H. M. (2008). Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 88: 660-666 [Abstract] [Full Text]  
• Melamed, M. L., Bauer, C., Hostetter, T. H. (2008). eGFR: Is It Ready for Early Identification of CKD?. CJASN 3: 1569-1572 [Abstract] [Full Text]  
• Xie, D., Joffe, M. M., Brunelli, S. M., Beck, G., Chertow, G. M., Fink, J. C., Greene, T., Hsu, C.-y., Kusek, J. W., Landis, R., Lash, J., Levey, A. S., O'Conner, A., Ojo, A., Rahman, M., Townsend, R. R., Wang, H., Feldman, H. I. (2008). A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. CJASN 3: 1332-1338 [Abstract] [Full Text]  
• Breyer, M. D. (2008). Stacking the Deck for Drug Discovery in Diabetic Nephropathy: In Search of an Animal Model. J. Am. Soc. Nephrol. 19: 1623-1624 [Full Text]  
• Schindler, C. (2008). ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET. Therapeutic Advances in Cardiovascular Disease 2: 233-248 [Abstract]  
• Chun, T.-Y., Chander, P. N., Kim, J.-W., Pratt, J. H., Stier, C. T. Jr. (2008). Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats. Am. J. Physiol. Endocrinol. Metab. 295: E305-E312 [Abstract] [Full Text]  
• Crowley, S. D., Frey, C. W., Gould, S. K., Griffiths, R., Ruiz, P., Burchette, J. L., Howell, D. N., Makhanova, N., Yan, M., Kim, H.-S., Tharaux, P.-L., Coffman, T. M. (2008). Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am. J. Physiol. Renal Physiol. 295: F515-F524 [Abstract] [Full Text]  
• Kolesnyk, I., Noordzij, M., Dekker, F. W., Boeschoten, E. W., Krediet, R. T. (2008). A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 0: gfn421v1-gfn421 [Abstract] [Full Text]  
• Satoh, M., Fujimoto, S., Arakawa, S., Yada, T., Namikoshi, T., Haruna, Y., Horike, H., Sasaki, T., Kashihara, N. (2008). Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant 0: gfn357v1-gfn357 [Abstract] [Full Text]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• Onuigbo, M.A.C., Onuigbo, N.T.C. (2008). Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. QJM 101: 519-527 [Abstract] [Full Text]  
• Abaterusso, C., Lupo, A., Ortalda, V., De Biase, V., Pani, A., Muggeo, M., Gambaro, G. (2008). Treating Elderly People with Diabetes and Stages 3 and 4 Chronic Kidney Disease. CJASN 3: 1185-1194 [Abstract] [Full Text]  
• Carey, R. M. (2008). Antihypertensive and Renoprotective Mechanisms of Renin Inhibition in Diabetic Rats. Hypertension 52: 63-64 [Full Text]  
• Feldman, D. L., Jin, L., Xuan, H., Contrepas, A., Zhou, Y., Webb, R. L., Mueller, D. N., Feldt, S., Cumin, F., Maniara, W., Persohn, E., Schuetz, H., Jan Danser, A.H., Nguyen, G. (2008). Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats. Hypertension 52: 130-136 [Abstract] [Full Text]  
• Farbom, P., Wahlstrand, B., Almgren, P., Skrtic, S., Lanke, J., Weiss, L., Kjeldsen, S., Hedner, T., Melander, O. (2008). Interaction Between Renal Function and Microalbuminuria for Cardiovascular Risk in Hypertension: The Nordic Diltiazem Study. Hypertension 52: 115-122 [Abstract] [Full Text]  
• Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., Hollenberg, N. K., the AVOID Study Investigators, (2008). Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. NEJM 358: 2433-2446 [Abstract] [Full Text]  
• Heerspink, H. L., Greene, T., Lewis, J. B., Raz, I., Rohde, R. D., Hunsicker, L. G., Schwartz, S. L., Aronoff, S., Katz, M. A., Eisner, G. M., Mersey, J. H., Wiegmann, T. B., for the Collaborative Study Group, (2008). Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 23: 1946-1954 [Abstract] [Full Text]  
• Mima, A., Arai, H., Matsubara, T., Abe, H., Nagai, K., Tamura, Y., Torikoshi, K., Araki, M., Kanamori, H., Takahashi, T., Tominaga, T., Matsuura, M., Iehara, N., Fukatsu, A., Kita, T., Doi, T. (2008). Urinary Smad1 Is a Novel Marker to Predict Later Onset of Mesangial Matrix Expansion in Diabetic Nephropathy. Diabetes 57: 1712-1722 [Abstract] [Full Text]  
• Ruggenenti, P., Perticucci, E., Cravedi, P., Gambara, V., Costantini, M., Sharma, S. K., Perna, A., Remuzzi, G. (2008). Role of Remission Clinics in the Longitudinal Treatment of CKD. J. Am. Soc. Nephrol. 19: 1213-1224 [Full Text]  
• Karalliedde, J., Smith, A., DeAngelis, L., Mirenda, V., Kandra, A., Botha, J., Ferber, P., Viberti, G. (2008). Valsartan Improves Arterial Stiffness in Type 2 Diabetes Independently of Blood Pressure Lowering. Hypertension 51: 1617-1623 [Abstract] [Full Text]  
• Schocken, D. D., Benjamin, E. J., Fonarow, G. C., Krumholz, H. M., Levy, D., Mensah, G. A., Narula, J., Shor, E. S., Young, J. B., Hong, Y. (2008). Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117: 2544-2565 [Abstract] [Full Text]  
• MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., McMurray, J. J.V. (2008). Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 29: 1224-1240 [Abstract] [Full Text]  
• Dubel, G. J, Murphy, T. P (2008). The role of percutaneous revascularization for renal artery stenosis. Vasc Med 13: 141-156 [Abstract]  
• Mitterbauer, C., Heinze, G., Kainz, A., Kramar, R., Horl, W. H., Oberbauer, R. (2008). ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant 23: 1742-1746 [Abstract] [Full Text]  
• Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D., Navis, G. (2008). Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan. J. Am. Soc. Nephrol. 19: 999-1007 [Abstract] [Full Text]  
• Siragy, H. M., Huang, J. (2008). Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp Physiol 93: 709-714 [Abstract] [Full Text]  
• Betteridge, D. J., DeFronzo, R. A., Chilton, R. J. (2008). PROactive: time for a critical appraisal. Eur Heart J 29: 969-983 [Abstract] [Full Text]  
• Weinrauch, L. A., Lin, J., Solomon, S. D. (2008). Mapping Directions for the Cardiorenal Conundrum: Where You End Up Depends Upon Where You Started, So Where Do We Go From Here?. J Am Coll Cardiol 51: 1275-1276 [Full Text]  
• Bloomgarden, Z. T. (2008). Diabetic Nephropathy. Diabetes Care 31: 823-827 [Abstract] [Full Text]  
• Postma, M. J., Boersma, C., Gansevoort, R. T. (2008). Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. Nephrol Dial Transplant 23: 1103-1106 [Full Text]  
• Nikzamir, A., Nakhjavani, M., Esteghamati, A., Rashidi, A. (2008). Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition. Nephrol Dial Transplant 23: 1274-1277 [Abstract] [Full Text]  
• Palmer, A. J., Valentine, W. J., Chen, R., Mehin, N., Gabriel, S., Bregman, B., Rodby, R. A. (2008). A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 23: 1216-1223 [Abstract] [Full Text]  
• Parving, H.-H., de Zeeuw, D., Cooper, M. E., Remuzzi, G., Liu, N., Lunceford, J., Shahinfar, S., Wong, P. H., Lyle, P. A., Rossing, P., Brenner, B. M. (2008). ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy. J. Am. Soc. Nephrol. 19: 771-779 [Abstract] [Full Text]  
• Tikellis, C., Bialkowski, K., Pete, J., Sheehy, K., Su, Q., Johnston, C., Cooper, M. E., Thomas, M. C. (2008). ACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes. Diabetes 57: 1018-1025 [Abstract] [Full Text]  
• Durvasula, R. V., Shankland, S. J. (2008). Activation of a local renin angiotensin system in podocytes by glucose. Am. J. Physiol. Renal Physiol. 294: F830-F839 [Abstract] [Full Text]  
• Coffman, T. M., Crowley, S. D. (2008). Kidney in Hypertension: Guyton Redux. Hypertension 51: 811-816 [Full Text]  
• Astor, B.C., Yi, S., Hiremath, L., Corbin, T., Pogue, V., Wilkening, B., Peterson, G., Lewis, J., Lash, J.P., Van Lente, F., Gassman, J., Wang, X., Bakris, G., Appel, L.J., Contreras, G. (2008). N-Terminal Prohormone Brain Natriuretic Peptide as a Predictor of Cardiovascular Disease and Mortality in Blacks With Hypertensive Kidney Disease: The African American Study of Kidney Disease and Hypertension (AASK). Circulation 117: 1685-1692 [Abstract] [Full Text]  
• Kelly, C. J., Booth, G. (2008). Pharmacist-led structured care for patients with diabetic nephropathy. British Journal of Diabetes & Vascular Disease 8: 86-88 [Abstract]  
• Jaar, B. G., Khatib, R., Plantinga, L., Boulware, L. E., Powe, N. R. (2008). Principles of Screening for Chronic Kidney Disease. CJASN 3: 601-609 [Full Text]  
• Tershakovec, A. M., Keane, W. F., Zhang, Z., Lyle, P. A., Appel, G. B., McGill, J. B., Parving, H.-H., Cooper, M. E., Shahinfar, S., Brenner, B. M. (2008). Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study. Diabetes Care 31: 445-447 [Abstract] [Full Text]  
• Gradman, A. H., Kad, R. (2008). Renin inhibition in hypertension.. J Am Coll Cardiol 51: 519-528 [Abstract] [Full Text]  
• HORNICK, T., ARON, D. C. (2008). Preventing and managing diabetic complications in elderly patients. Cleveland Clinic Journal of Medicine 75: 153-158 [Abstract] [Full Text]  
• Izuhara, Y., Nangaku, M., Takizawa, S., Takahashi, S., Shao, J., Oishi, H., Kobayashi, H., van Ypersele de Strihou, C., Miyata, T. (2008). A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 23: 497-509 [Abstract] [Full Text]  
• de Zeeuw, D., Raz, I. (2008). Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes. Diabetes Care 31: S190-S193 [Full Text]  
• Basi, S., Fesler, P., Mimran, A., Lewis, J. B. (2008). Microalbuminuria in Type 2 Diabetes and Hypertension: A marker, treatment target, or innocent bystander?. Diabetes Care 31: S194-S201 [Full Text]  
• Osher, E., Stern, N. (2008). Diastolic Pressure in Type 2 Diabetes: Can target systolic pressure be reached without "diastolic hypotension"?. Diabetes Care 31: S249-S254 [Abstract] [Full Text]  
• Yagi, S., Aihara, K.-i., Ikeda, Y., Sumitomo, Y., Yoshida, S., Ise, T., Iwase, T., Ishikawa, K., Azuma, H., Akaike, M., Matsumoto, T. (2008). Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency. Circ. Res. 102: 68-76 [Abstract] [Full Text]  
• Knoll, G. A., Cantarovitch, M., Cole, E., Gill, J., Gourishankar, S., Holland, D., Kiberd, B., Muirhead, N., Prasad, R., Tibbles, L. A., Treleaven, D., Fergusson, D. (2008). The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design. Nephrol Dial Transplant 23: 354-358 [Abstract] [Full Text]  
• Steigerwalt, S. (2008). Management of Hypertension in Diabetic Patients With Chronic Kidney Disease. Diabetes Spectr. 21: 30-36 [Abstract] [Full Text]  
• van Domburg, R. T., Hoeks, S. E., Welten, G. M.J.M., Chonchol, M., Elhendy, A., Poldermans, D. (2008). Renal Insufficiency and Mortality in Patients with Known or Suspected Coronary Artery Disease. J. Am. Soc. Nephrol. 19: 158-163 [Abstract] [Full Text]  
• Kunz, R., Friedrich, C., Wolbers, M., Mann, J. F.E. (2008). Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. ANN INTERN MED 148: 30-48 [Abstract] [Full Text]  
• de Cavanagh, E. M. V., Ferder, L., Toblli, J. E., Piotrkowski, B., Stella, I., Fraga, C. G., Inserra, F. (2008). Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes. Am. J. Physiol. Heart Circ. Physiol. 294: H456-H465 [Abstract] [Full Text]  
• Linas, S. L. (2008). Managing CKD: Key Therapeutic Issues Introduction. CJASN 3: S1-S2 [Full Text]  
• Bakris, G. L. (2008). Slowing Nephropathy Progression: Focus on Proteinuria Reduction. CJASN 3: S3-S10 [Abstract] [Full Text]  
• American Diabetes Association, (2008). Standards of Medical Care in Diabetes--2008. Diabetes Care 31: S12-S54 [Full Text]  
• McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z. (2007). Health of Previously Uninsured Adults After Acquiring Medicare Coverage. JAMA 298: 2886-2894 [Abstract] [Full Text]  
• Burnier, M. (2007). Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective. Journal of Renin-Angiotensin-Aldosterone System 8: 208-211  
• Sinclair, A., Appel, G., Dooley, M.A., Ginzler, E., Isenberg, D., Jayne, D., Wofsy, D., Solomons, N. (2007). Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16: 972-980 [Abstract]  
• Bloom, R. D., Reese, P. P. (2007). Chronic Kidney Disease after Nonrenal Solid-Organ Transplantation. J. Am. Soc. Nephrol. 18: 3031-3041 [Abstract] [Full Text]  
• Zandbergen, A. A.M., Vogt, L., de Zeeuw, D., Lamberts, S. W.J., Ouwendijk, R. J.T.H., Baggen, M. G.A., Bootsma, A. H. (2007). Change in Albuminuria Is Predictive of Cardiovascular Outcome in Normotensive Patients With Type 2 Diabetes and Microalbuminuria. Diabetes Care 30: 3119-3121 [Full Text]  
• Palm, F., Onozato, M. L., Luo, Z., Wilcox, C. S. (2007). Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am. J. Physiol. Heart Circ. Physiol. 293: H3227-H3245 [Abstract] [Full Text]  
• Gao, S., Manns, B. J., Culleton, B. F., Tonelli, M., Quan, H., Crowshoe, L., Ghali, W. A., Svenson, L. W., Hemmelgarn, B. R., for the Alberta Kidney Disease Network, (2007). Prevalence of Chronic Kidney Disease and Survival among Aboriginal People. J. Am. Soc. Nephrol. 18: 2953-2959 [Abstract] [Full Text]  
• Liu, S., Shi, L., Wang, S. (2007). Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney injury. Am. J. Physiol. Renal Physiol. 293: F1727-F1735 [Abstract] [Full Text]  
• Whaley-Connell, A., Pavey, B. S., Chaudhary, K., Saab, G., Sowers, J. R. (2007). Review: Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Therapeutic Advances in Cardiovascular Disease 1: 27-35 [Abstract]  
• Joss, N., Patel, R., Paterson, K., Simpson, K., Perry, C., Stirling, C. (2007). Anaemia is common and predicts mortality in diabetic nephropathy. QJM 100: 641-647 [Abstract] [Full Text]  
• Authors/Task Force Members, , Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., Gjelsvik, B., Herrmann-Lingen, C., Hoes, A., Humphries, S., Knapton, M., Perk, J., Priori, S. G., Pyorala, K., Reiner, Z., Ruilope, L., Sans-Menendez, S., Scholte op Reimer, W., Weissberg, P., Wood, D., Yarnell, J., Zamorano, J. L., Other experts who contributed to parts of the guid, , Walma, E., Fitzgerald, T., Cooney, M. T., Dudina, A., European Society of Cardiology (ESC) Committee for, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Funck-Brentano, C., Filippatos, G., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document reviewers:, , Hellemans, I., Altiner, A., Bonora, E., Durrington, P. N., Fagard, R., Giampaoli, S., Hemingway, H., Hakansson, J., Kjeldsen, S. E., Larsen, M. L., Mancia, G., Manolis, A. J., Orth-Gomer, K., Pedersen, T., Rayner, M., Ryden, L., Sammut, M., Schneiderman, N., Stalenhoef, A. F., Tokgozoglu, L., Wiklund, O., Zampelas, A. (2007). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 28: 2375-2414 [Full Text]  
• Perkovic, V., Ninomiya, T., Arima, H., Gallagher, M., Jardine, M., Cass, A., Neal, B., MacMahon, S., Chalmers, J. (2007). Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering: Data from the PROGRESS Study. J. Am. Soc. Nephrol. 18: 2766-2772 [Abstract] [Full Text]  
• Tan, Y., Keum, J.-S., Wang, B., McHenry, M. B., Lipsitz, S. R., Jaffa, A. A. (2007). Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am. J. Physiol. Renal Physiol. 293: F1026-F1035 [Abstract] [Full Text]  
• Hitomi, H., Kiyomoto, H., Nishiyama, A., Hara, T., Moriwaki, K., Kaifu, K., Ihara, G., Fujita, Y., Ugawa, T., Kohno, M. (2007). Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells. Hypertension 50: 750-755 [Abstract] [Full Text]  
• Glynn, L. G., Reddan, D., Newell, J., Hinde, J., Buckley, B., Murphy, A. W. (2007). Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant 22: 2586-2594 [Abstract] [Full Text]  
• Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R., Kopp, J. B. (2007). Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis. CJASN 2: 906-913 [Abstract] [Full Text]  
• Riedl, E., Koeppel, H., Brinkkoetter, P., Sternik, P., Steinbeisser, H., Sauerhoefer, S., Janssen, B., van der Woude, F. J., Yard, B. A. (2007). A CTG Polymorphism in the CNDP1 Gene Determines the Secretion of Serum Carnosinase in Cos-7 Transfected Cells. Diabetes 56: 2410-2413 [Abstract] [Full Text]  
• Smith, R. J.H., Alexander, J., Barlow, P. N., Botto, M., Cassavant, T. L., Cook, H. T., de Cordoba, S. R., Hageman, G. S., Jokiranta, T. S., Kimberling, W. J., Lambris, J. D., Lanning, L. D., Levidiotis, V., Licht, C., Lutz, H. U., Meri, S., Pickering, M. C., Quigg, R. J., Rops, A. L., Salant, D. J., Sethi, S., Thurman, J. M., Tully, H. F., Tully, S. P., van der Vlag, J., Walker, P. D., Wurzner, R., Zipfel, P. F., Dense Deposit Disease Focus Group, (2007). New Approaches to the Treatment of Dense Deposit Disease. J. Am. Soc. Nephrol. 18: 2447-2456 [Abstract] [Full Text]  
• Chobanian, A. V. (2007). Isolated Systolic Hypertension in the Elderly. NEJM 357: 789-796 [Full Text]  
• Wong, D. W., Oudit, G. Y., Reich, H., Kassiri, Z., Zhou, J., Liu, Q. C., Backx, P. H., Penninger, J. M., Herzenberg, A. M., Scholey, J. W. (2007). Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury. Am. J. Pathol. 171: 438-451 [Abstract] [Full Text]  
• McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z. (2007). Use of Health Services by Previously Uninsured Medicare Beneficiaries. NEJM 357: 143-153 [Abstract] [Full Text]  
• Schiffrin, E. L., Lipman, M. L., Mann, J. F.E. (2007). Chronic Kidney Disease: Effects on the Cardiovascular System. Circulation 116: 85-97 [Abstract] [Full Text]  
• Hardy, K. J, Furlong, N. J, Hulme, S. A, O'Brien, S. V (2007). Delivering improved management and outcomes in diabetic kidney disease in routine clinical care. British Journal of Diabetes & Vascular Disease 7: 172-182 [Abstract]  
• Cavanaugh, K. L. (2007). Diabetes Management Issues for Patients With Chronic Kidney Disease. Clin. Diabetes 25: 90-97 [Abstract] [Full Text]  
• Jin, H.-M., Pan, Y. (2007). Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrol Dial Transplant 22: 1943-1949 [Abstract] [Full Text]